echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hausen Pharmaceuticals' new adaptation of Ametinib is approved for the first-line treatment of non-small cell lung cancer

    Hausen Pharmaceuticals' new adaptation of Ametinib is approved for the first-line treatment of non-small cell lung cancer

    • Last Update: 2021-12-26
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Pharmaceutical Guanlan

    On December 16, the official website of China's National Food and Drug Administration (NMPA) announced that Hausen Pharmaceuticals' third-generation EGFR-TKI Ametinib had been approved for a new indication


    Image source: NMPA official website

    Ametinib is a third-generation EGFR (epidermal growth factor receptor)-TKI (tyrosine kinase inhibitor) developed by Hausen Pharmaceuticals


    In May 2021, the marketing application for new indications of Ametinib was included in the priority review by CDE


    Image source: CDE official website

    According to a press release issued by Hausen Pharmaceuticals, the company is currently exploring many new indications for Ametinib, including targeted combination chemotherapy, targeted anti-vascular therapy, and so on


    Note: The original text has been deleted

    Reference materials:

    [1] Information to be obtained for the drug approval certificate issued by the National Medical Products Administration of China on December 16.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.